•
Cisplatin-based chemotherapy is the preferred first-line treatment for
metastatic urothelial cancer and the only treatment shown to
improve survival in patients with previously untreated disease.
•
However, only a minority of patients with metastatic urothelial cancer
receive first-line treatment with cisplatin-based chemotherapy.
The 1L non-cisplatin elegible
